Flunarizine, an anti-migraine agent, impairs nitroxidergic nerve function in cerebral arteries

European Journal of Pharmacology

Volumn 329, Issue 1, 1997, Pages 49-53

  Ayajiki, Kazuhide ^a   Okamura, Tomio ^a   Toda, Noboru ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Flunarizine; Migraine; Nitric oxide (NO); Vasodilator nerve

Indexed keywords

ANTIMIGRAINE AGENT; CALCIUM CHANNEL BLOCKING AGENT RECEPTOR; FLUNARIZINE; HEXAMETHONIUM BROMIDE; NICOTINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PAPAVERINE; SUBSTANCE P;

ANIMAL TISSUE; ARTERY DILATATION; ARTICLE; BRAIN ARTERY; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG MECHANISM; ELECTROSTIMULATION; FEMALE; MALE; MIGRAINE; NERVE FUNCTION; NERVE STIMULATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0031577193     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)10103-0     Document Type: Article

References (30)

1. Araki G., Saito T., Ishii A. Phase I study of KW-3149 (flunarizine hydrochloride). Kiso to Rinsho. 16:1982;171-177. in Japanese.
2. Frenken C.W.G.M., Nuijten S.T.M. Flunarizine, a new preventive approach to migraine. Clin. Neurol. Neurosurg. 86:1984;17-20.
3. Furchgott, R.F., 1988. Studies on relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that the acid-activatable inhibitory factor from bovine retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide. In: Vanhoutte, P.M. (Eds.), Vasodilatation, Raven Press, New York, NY, pp. 401-414.
4. Harper A.M., Craigen L., Kazda S. Effect of the calcium antagonist, nimodipine, on cerebral blood flow and metabolism in the primate. J. Cerebr. Blood Flow Metab. 1:1981;349-356.
5. Holmes B., Brogden R.N., Heel R.C., Speight T.M., Avery G.S. Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drug. 27:1984;6-44.
6. Hosono M., Fujii S., Hiruma T., Watanabe K., Hayashi Y., Ohnishi H., Takata Y., Kato H. Inhibitory effect of cilnidipine on vascular sympathetic neurotransmission and subsequent vasoconstriction in spontaneously hypertensive rats. Jpn. J. Pharmacol. 69:1995;127-134.
7. Iversen H.K., Olesen J., Tfelt-Hansen P. Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain. 38:1989;17-24.
8. Leone M., Grazzi L., La Mantia L., Bussone G. Flunarizine in migraine: a minireview. Headache. 31:1991;388-391.
9. Louis P. A double-blind placebo-controlled prophylactic study of flunarizine in migraine. Headache. 21:1981;235-239.
10. McCleskey E.W., Fox A.P., Tsien R.W., Yoshikami D. ω-Conotoxin, direct and persistent blockade of specific types of calcium channels in neurons but not muscle. Proc. Natl. Acad. Sci. USA. 84:1987;4327-4331.
11. Mendenopoulos G., Manafi T., Logothesis I., Bostantjopoulou S. Flunarizine in the prevention of classical migraine: a placebo-controlled evaluation. Cephalalgia. 5:1985;31-37.
12. Nedergaard, O.A., 1988. Effect of nicotine on neuroeffector transmission in blood vessels. In: Rand, M., Thurau, K. (Eds.) The Pharmacology of Nicotine. IRL Press, Washington, DC, pp. 143-162.
13. Nishikawa M., Okamura T., Toda N. Effect of the novel calcium antagonist AE0047 on responses of isolated dog blood vessels to vasoconstricting agents and to nerve stimulation. Folia Pharmacol. Jpn. 106:1995;19-29. text in Japanese, abstract in English.
14. 2+ entry blocker, inhibits the responses to adrenergic nerve stimulation and substance P in dog mesenteric arteries. Eur. J. Pharmacol. 220:1992;27-33.
15. Olesen J., Thomsen L.L., Iversen H. Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol. Sci. 15:1994;149-153.
16. 2+ channel blockers: multiple sites of action. Folia Pharmacol. Jpn. 100:1992;239-247. text in Japanese, abstract in English.
17. Sorensen P.S., Hansen K., Olesen J. A placebo-controlled, double-blind, cross-over trial of flunarizine in common migraine. Cephalalgia. 6:1986;7-14.
18. Sorge F., Marano E. Flunarizine v. placebo in childhood migraine. A double-blind study. Cephalalgia. 5(Suppl. 2):1985;145-148.
19. Sorge F., De Simone R., Marano E., Nolano M., Orefice G., Carrieri P. Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled, cross-over study. Cephalalgia. 8:1988;1-6.
20. Tanaka K., Gotoh F., Muramatsu F., Fukuuchi Y., Amano T., Okayasu H., Suzuki N. Effects of nimodipine (Bay e 9736) on cerebral circulation in cats. Arzneim.-Forsch. 30:1980;1494-1497.
21. Toda N. Relaxant responses to transmural stimulation and nicotine of dog and monkey cerebral arteries. Am. J. Physiol. 243:1982;H145-H153.
22. Toda, N., 1993. Endothelial and neural nitric oxide-induced cerebral artery dilatation. In: Olesen, J., Schmidt, R.F. (Eds.), Pathophysiological Mechanisms of Migraine, VCH Publishers, New York, NY, pp. 37-43.
23. Toda N., Okamura T. Possible role of nitric oxide in transmitting information from vasodilator nerve to cerebroarterial muscle. Biochem. Biophy. Res. Commun. 170:1990;308-313.
24. Toda N., Okamura T. Role of nitric oxide in neurally induced cerebroarterial relaxation. J. Pharmacol. Exp. Ther. 258:1991;1027-1032.
25. Toda N., Okamura T. Regulation by nitroxidergic nerve of arterial tone. News Physiol. Sci. 7:1992;148-152.
26. ++ antagonists in cerebral arteries. J. Pharmacol. Exp. Ther. 261:1992;234-239.
27. Toda, N., Tfelt-Hansen, P., 1993. Calcium antagonists, In: Olesen, J., Tfelt-Hansen, P., Welch, K.M.A. (Eds.), Raven Press, New York, NY, pp. 383-390.
28. Toda N., Kitamura Y., Okamura T. Role of nitroxidergic nerve in dog retinal arterioles in vivo and arteries in vitro. Am. J. Physiol. 266:1994;H1985-H1992.
29. Toda N., Uchiyama M., Okamura T. Prejunctional modulation of nitroxidergic nerve function in canine cerebral arteries. Brain Res. 700:1995;213-218.
30. Tytgat J., Pauwels P.J., Vereecke J., Carmeliet E. Flunarizine inhibits a high-threshold inactivating calcium channel (N-type) in isolated hippocampal neurons. Brain Res. 549:1991;112-117.